Long-Term Safety of 30 mg and 60 mg Oral Daily Dose of Ospemifene in the Treatment of Vulvar and Vaginal Atrophy (VVA) in Postmenopausal Women With Intact Uterus

PHASE3CompletedINTERVENTIONAL

Enrollment

180

Participants

Timeline

Start Date

May 16, 2006

Primary Completion Date

August 19, 2008

Study Completion Date

September 18, 2008

Conditions

AtrophyVaginal Diseases

Interventions

DRUG

Ospemifene (Dose 1)

DRUG

Ospemifene (Dose 2)

DRUG

Placebo